#United States #New York #Gross Law Firm #Pacira BioSciences #PCRX

Pacira BioSciences Shareholders, Important Notice of Class Action Lawsuit

On March 6, 2025, The Gross Law Firm issued a crucial notification for shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). This notice addresses an ongoing class action lawsuit, urging shareholders who acquired shares during the mentioned period to take prompt action.

Shareholder Information

During the time frame from August 2, 2023, to August 8, 2024, shareholders may be eligible to join this significant legal action. It is essential for those impacted to reach out to The Gross Law Firm regarding their potential appointment as lead plaintiff. However, it's important to note that you do not need to be appointed as the lead plaintiff to participate and benefit from any recovery resulting from this lawsuit.

Allegations Against Pacira BioSciences

The allegations surrounding this class action stem from a press release issued by Pacira on August 9, 2024. This release revealed that the results of a lawsuit against eVenus regarding patent infringement led to unfavorable findings. Specifically, the U.S. Patent No. 11,033,495, critical to Pacira's primary revenue-generating product, Exparel, was deemed invalid by the court. Given that this patent accounts for approximately 80% of the company's revenue, its invalidation raises serious concerns about the validity of Pacira's other patents.

Industry analysts have expressed worries that the invalidity ruling could encourage generic drug manufacturers to enter the market, further leading to an increase in litigation costs for Pacira. In a dramatic market reaction, following the announcement, shares of Pacira plummeted from a closing price of $22.36 per share on August 8, 2024, to a low of $11.70 per share the next day, marking a staggering decline of over 47%.

Important Deadlines for Shareholders

It is crucial for shareholders to act quickly. The deadline to register for this class action lawsuit is March 14, 2025. Interested parties can register through the link provided by The Gross Law Firm, ensuring they are included in any possible recovery.

Once registered, shareholders will benefit from portfolio monitoring software, which will keep them updated on the case's status. Registration to be part of this case involves no costs or obligations, ensuring ease of participation.

Why Choose The Gross Law Firm?

The Gross Law Firm has established itself as a reputable class action law firm on a national scale. Their commitment is to protect investors' rights who may have suffered losses due to fraudulent or misleading business practices. Their mission is to assist investors harmed by companies engaged in deceptive practices that inflate stock prices or omit vital information.

For any inquiries or to enroll in this class action, shareholders can contact The Gross Law Firm at their New York office:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

This case highlights the importance of holding companies accountable for their business practices. Shareholders of Pacira BioSciences, be proactive—ensure your voice is heard and your rights protected. Act before the deadline and explore your options for recovery in this unfolding situation.